Nonalcoholic fatty liver disease and liver transplantation – Where do we stand?
| Autor: | Ivana Mikolašević, Sandra Milić, Maja Mijić, Davor Štimac, Nikola Sobočan, Ivan Jakopčić, Tajana Filipec-Kanizaj, Irena Hrstić, Patrizia Burra |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Liver Cirrhosis
Cirrhosis medicine.medical_treatment Comorbidity Review Liver transplantation Chronic liver disease Gastroenterology 0302 clinical medicine Non-alcoholic Fatty Liver Disease Recurrence Risk Factors Nonalcoholic fatty liver disease Prevalence Medicine Outcome BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina Metabolic Syndrome liver transplantation Incidence Graft Survival Liver Neoplasms General Medicine Nonalcoholic steatohepatitis Liver 030220 oncology & carcinogenesis Hepatocellular carcinoma 030211 gastroenterology & hepatology medicine.medical_specialty Tissue and Organ Procurement Waiting Lists digestive system 03 medical and health sciences Internal medicine Humans BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine business.industry nutritional and metabolic diseases nonalcoholic fatty liver disease nonalcoholic steatohepatitis chronic liver disease outcome medicine.disease digestive system diseases Transplantation Metabolic syndrome business |
| Zdroj: | World Journal of Gastroenterology Volume 24 Issue 14 |
| ISSN: | 1007-9327 2219-2840 |
| Popis: | Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) is a challenging and multisystem disease that has a high socioeconomic impact. NAFLD/ NASH is a main cause of macrovesicular steatosis and has multiple impacts on liver transplantation (LT), on patients on the waiting list for transplant, on posttransplant setting as well as on organ donors. Current data indicate new trends in the area of chronic liver disease. Due to the increased incidence of metabolic syndrome (MetS) and its components, NASH cirrhosis and hepatocellular carcinoma caused by NASH will soon become a major indication for LT. Furthermore, due to an increasing incidence of MetS and, consequently, NAFLD, there will be more steatotic donor livers and less high quality organs available for LT, in addition to a lack of available liver allografts. Patients who have NASH and are candidates for LT have multiple comorbidities and are unique LT candidates. Finally, we discuss long-term grafts and patient survival after LT, the recurrence of NASH and NASH appearing de novo after transplantation. In addition, we suggest topics and areas that require more research for improving the health care of this increasing patient population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|